Laurus Labs

Grounded in Values, Growing in Capability.

Integrated Annual Report FY 2025-26

Read More
Laurus Labs manufacturing

About the Report

This Integrated Report presents a holistic view of Laurus' performance for FY 2025-26, bringing together financial and non-financial disclosures to explain how we create and sustain value over time.

Read More
FY 2025-26 HIGHLIGHTS

Momentum Built
on Capability

Know More

Financial

6,813 crore
Revenue from operations
23%
1,826 crore
EBITDA
64%
26.8%
EBITDA margin
6.7 bps
889 crore
Profit after tax
148%
14.6%
Dividend payout ratio
y-o-y growth
17.7%
Return on capital employed
8% pp

Operational

Advancing Peptides development & manufacturing infrastructure in Vizag to support fully integrated programmes

Established Gene therapy / ADC process development lab in Hyderabad

Accelerating greenfield capacity creation for microbial fermentation in Vizag Completed

ESG

0 GJ
Energy from renewable sources
0 KL
Water recycled or reused
9%
Female employees
0
Man-hours spent on health and safety training
50%
Independent Directors
20%
Women Directors
Laurus at a Glance
Laurus at a Glance

Advancing Science
with Purpose

Guided by the principle “Chemistry for Better Living”, we are advancing science through differentiated capabilities that expand access, enable innovation and support better health outcomes across global markets.

Dr. K. Ravindranath

Chairman's Statement

Dear Stakeholders,
As Laurus marks two decades of its journey, FY 2025-26 stands as a year that reflects both progress and perspective.

Dr. K. Ravindranath
Non-Executive Chairman and
Independent Director

Read More
Dr. Satyanarayana Chava

CEO's Message

Dear Stakeholders,
As we complete 20 years, I am pleased to share that, guided by our purpose of improving lives through our chemistry expertise, we continued to address evolving healthcare needs while building enduring value for our stakeholders.

Dr. Satyanarayana Chava
Executive Director and
Chief Executive Officer

Read More
Business Review Affordable Medicines – API

Grounded in Science,
Growing in Scale.

Operating Environment

Macro Trends Shaping our Business

Global CDMO demand continues to rise, supported by sustained R&D spending, supply-chain diversification and growing demand for specialised outsourced capabilities, notwithstanding near-term challenges.

Read More
Manufacturing Strength

Advancing our Manufacturing Capability

Investments continued across our facilities spanning CDMO, Affordable Medicines and FDF. These expansions are reinforcing our commitment to being a high-quality development and manufacturing partner at scale, including in advanced therapies.

15 sites
Manufacturing network
8,200 KL
Reactor capacity
12 billion units
Formulation capacity
240 KL
Fermentation capacity
Read More
R&D Edge

Deepening our Scientific Capability

As the business expands into more complex molecules and emerging therapeutic areas, our R&D efforts are focused on enabling scalable processes, strengthening platform technologies and accelerating the transition from development to commercialisation.

282 Crore
R&D spend
4%
R&D spend as a share of revenue
68
Projects supported
94
DS/DP launches
Read More
Quality and Compliance

Grounded in Values, Strengthened by Systems.

Quality is a foundational principle that shapes how we operate, how we scale and how we build long-term credibility with customers and regulators.

Read More
Information Technology

Grounded in Systems, Growing through Intelligence

Our digital strategy is focused on building a resilient, secure and scalable technology backbone, while progressively embedding digital tools across operations to enhance efficiency, strengthen compliance and enable data-driven decision-making across the organisation.

ISO 27001:2022
Certified information security framework
100% Locations
Network Access Control (NAC) implemented
6
Phishing simulation and awareness drives
100%
Incidents of Data Breaches
Read More
Strategic Priorities

Innovate. Excel. Expand

We are advancing our strategy through three focused pillars: Innovate, Excel and Expand — reflecting our commitment to strengthening scientific capabilities, execution discipline and scalable infrastructure.

01

Innovate

Strategic Objectives
  • R&D-led diversification and integrated offerings
  • Investment in disruptive innovation
  • Advancing new technology platforms
  • Digitisation and automation
02

Excel

Strategic Objectives
  • Strong product portfolio and customer-centric approach
  • Operational excellence and regulatory compliance
  • Talent development and leadership culture
03

Expand

Strategic Objectives
  • Large-scale manufacturing and R&D infrastructure
  • Market and customer base expansion
  • Leveraging technology synergies
  • Sustainable growth and value creation
ESG Approach

Embedding ESG into
the Way We Grow

We integrate Environmental, Social and Governance (ESG) principles into our core business strategy, enabling responsible growth and long-term value creation.

Laurus Labs ESG approach
Employees

Growing through our People

Our people have been central to our success. We remain focused on building an organisation where talent, learning, safety and well-being evolve alongside business growth, enabling our teams to contribute meaningfully in a high-performance and values-driven environment.

Read More
Investors

Growing Shareholder Value

Read More
Governance

Values-led Governance for Long-term Growth

Read More

Awards & Recognition